AllArticlesConferencesCOVID-19MiscellaneousResearchUncategorizedAll Articles Conferences COVID-19 Miscellaneous Research Uncategorized RSNA 2021 || Fluidda introduces Broncholab application || November 28th – December 2nd || ChicagoFluidda introduces Broncholab application during the RSNA conference, Nov 28 – Dec 2, Chicago Broncholab uses a quantitative imaging tool called Functional Respiratory Imaging (FRI), which gives insights into the… View ArticleRSNA 2021 – Visit our Booth #4335 and learn all about BroncholabAre you attending RSNA 2021? Visit the Fluidda Booth #4335 and learn all about Broncholab. Fluidda will introduce their new Medical Device Broncholab at the RSNA Conference. Broncholab enables accurate… View ArticleFRI – Understanding the link between pulmonary vasculature abnormalities and DCLO in COVID-19FRI used to understand the link between pulmonary vasculature abnormalities and DCLO in COVID-19 In a recent article, Prof Daniel Salerno, Prof Victor Kim and colleagues used Functional Respiratory Imaging to better understand the crucial… View ArticleFRI improves patient selection for mandibular advancement device treatmentIn a recent published study Functional Respiratory Imaging (FRI) was used to assess Mandibular advancement devices (MAD) mechanisms. MAD are a non-invasive treatment option for patients with obstructive sleep apnea… View ArticleThe features and advantages of Fluidda’s FRI technologyFLUIDDA is the world leader in the field of Functional Respiratory Imaging. This technique combines HRCT scans and Computational Fluid Dynamics technology, enabling the assessment of treatment responses, and helping physicians to make… View ArticleThe Seven pillars of SAD in Asthma and COPDIn a recent publication in CHEST Journal, the importance of the small airways and their contribution to symptoms of asthma and COPD are discussed. Significant small airways dysfunction can be found… View ArticleFluidda’s Images Featured On Cover European Respiratory JournalFluidda’s vascular lung images featured on the cover of the digital European Respiratory Journal The European Respiratory Journal published a study (ERJ, impact factor 16.67) looking at the pulmonary blood… View ArticleFluidda Amongst Top Medical Imaging Providers 2021Healthcare Tech Outlook, a leading Healthcare technology print magazine, which provides a knowledge network for Healthcare Industry experts, awarded Fluidda as a “Top Ten” Medical Imaging Provider of the year… View ArticleFRI study shows the potential of an inhaled P13K delta inhibitor in COPD-exacerbations.A well powered study with FRI as primary endpoint shows the potential of an inhaled P13K delta inhibitor in COPD-exacerbations. A recent paper, published in the Int. Journal of Chronic Obstructive… View ArticleNew technique offers better lung care – Campaign The GuardianWe supported the Respiratory Health campaign that launched on Launch Date within the Guardian newspaper and online at https://bit.ly/3q3yTG6. Respiratory Health looked at key respiratory conditions, new innovations and the… View ArticleFluidda’s Broncholab issued Authorization with Conditions by Health Canada for Use in Relation to COVID-19In March 2020 Fluidda’s medical device called Broncholab was introduced in the USA. It is a diagnostic support tool to detect and to to improve therapy of lung diseases based on FRI technology. Broncholab will initially… View ArticleThe added value of FRI, explained by Dr. Muhunthan ThillaiDr. Muhunthan Thillai is a pulmonologist at Cambridge University, specialized in pulmonary fibrosis; and co-founder and CEO of Qur8, an imaging platform for analyzing large clinical sets of data. He is… View ArticleThe advent, value and place of QCT, Interview with Dr. Hoesein, UMCU.In the recently published “Fluidda’s Magazine on FRI”, Dr. Firdaus Hoesein, radiologist at the University Medical Centre Utrecht, was interviewed about his experiences with FRI and his expectations for the use… View Article“The need to Measure”, an interview with Dr. Langton on FRIIn the recently published “Fluidda’s Magazine on FRI”, Dr. Langton, pulmonologist at the University of Melbourne specialized in bronchial thermoplasty treatment, was interviewed about his experiences with FRI and his… View ArticleFluidda interviewed in “Precision Medicine” issue Pharma Focus AsiaIn the latest issue of the magazine Pharma Focus Asia, dedicated to precision medicine and personalizing health outcomes, the founders of Fluidda were interviewed. In this interview titled: “ Functional… View ArticleNovel FRI parameter analyzing the pulmonary vascular bed accurately predicts outcomes in COVID-19 disease, and can be decisive in choice of therapy.In a recent publication in the European Respiratory Journal (ERJ) by Morris et al. a retrospective analysis was performed of chest CT scans of 313 COVID-19 positive and 195 COVID-19 negative patients seeking acute medical care. From… View ArticleOver 5000 COVID-19 patients already analyzed with Fluidda’s new blood vessel volume FRI parameterWe are pleased to announce that CT scans of more than 5000 COVID-19 patients from all corners of the world have been analyzed with Fluidda’s recently developed BVX parameter! The BVX parameter… View ArticleDrug delivery and lung deposition using the Aerosphere™ inhaler, a study performed with FRI technology.Metered dose inhalers (MDI’s) are one of the most common device types for delivering inhaled therapies. However, there are several technical challenges in development and drug delivery of these medications…. View ArticleFluidda joins P4O2 ConsortiumPrevention is the key to healthy lungs.The quality of life for patients with chronic lung diseases like asthma, COPD, and lung cancer can- and should be improved. The Dutch consortium… View ArticlePredicting Lung Deposition of extrafine ICS Containing Fixed Combinations COPD patients using FRI in an in silico study.In a recent study by Usmani et al. , FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered… View ArticleNew FRI Article: Cluckers et al: Interstitial lung disease in systemic sclerosisFRI is able to differentiate moderate to severe versus limited disease and to detect disease progression in systemic sclerosis. Systemic sclerosis–associated ILD accounts for up to 20% of mortality in these patients… View ArticleTV News Show – January 14th – FRI in COVID-19 longhaulersFRI on PBS news hour: Medical community scrambles to understand COVID-19 ‘long haulers’ During a news item on PBS news hour, January 13, COVID-19 “long haulers” were discussed. Long haulers are COVID-19 patients… View ArticleFluidda’s COVID-19 consortiumToday, one year into the COVID-19 pandemic, we live in a changed world. With over a million deaths and many millions suffering long-term disability as a result of lasting damage… View ArticlePress release – Results PINTA trial Galapagos on IPF while using FRIGalapagos Announces Positive Topline Results in Phase 2 Study Using FRI Imaging Parameters While Investigating New Medication for IPF Patients. The PINTA trial was a randomized, double-blind, placebo-controlled trial investigating… View ArticleVisualisation FRI study – Effect lung deposition by adding an Aerochamber when using a pMDI in COPDEvaluations of inhaler use have demonstrated that mishandling of pMDIs (Pressurized Meter Dose Inhalers) is commonplace. One of the most common errors is the failure to coordinate inhalation with actuation… View ArticleFRI Biomarker OverviewThe added value of FRI in treating lung diseases. Fluidda developed a large number of HRCT-derived imaging parameters, based on its proprietary Functional Respiratory Imaging (FRI) technique, to generate very… View ArticleWorld COPD-Day 2020The use of Fluidda’s FRI technology in the combat against COPD. The exact prevalence of COPD worldwide is largely unknown, but estimates have varied from 7-19%. The Burden of Obstructive Lung Disease (BOLD) study… View ArticleBVX scans with COVID-patients – Delta HospitalDelta Hospital uses new imaging technology for better triage and optimal treatment of COVID-19 patients. Due to the very large number of Corona patients who now report daily for hospitalization,… View ArticlePoster CHEST 2020: AZ studie Maarten van den BergeFRI assessment of a fixed Triple Therapy (Bud/Gly/FF) and a fixed Dual Therapy (Gly/FF) in patients with COPD In a study presented as a poster at the virtual Chest conference, FRI was used… View ArticleFLUIDDA’s Online Site Training Course For Clinical Research SitesFluidda’s Online Site Training Course For Clinical Research Sites goes ” LIVE” For years Fluidda educates pulmonologists and CT-scanning personnel “on site” how to perform HRCT-scans that can be used in Clinical Trials… View ArticleThe Perfect StormTime for a paradigm shift in lung function research? The golden age of pulmonary function testing began in the 1920s, driven by the increasing prevalence of occupational lung disease and resulting interest… View ArticleFluidda’s FRI-activities are at “Full Speed” during this COVID-19 pandemicFluidda’s FRI-activities are at “Full Speed” during this COVID-19 pandemic The COVID-19 crisis has had a tremendous impact on the initiation and progression of clinical research around the world and… View ArticleP4O2 press release Netherlands Respiratory Society (NRS)A Public-private consortium P4O2 (Precision Medicine for more Oxygen) investigates risk factors for developing lung damage and chronic complaints after COVID-19. Many patients who have had COVID-19 continue to have… View ArticleAssessing short term effects of Orkambi on lung function in CF patientsFRI used to assess short-term effects of Orkambi on lung function in patients with CF homozygous for F508de The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator Orkambi (lumacaftor-ivacaftor) has shown modest benefits… View ArticleFluidda’s clinical research on COVID-19 in Belgian HCP-magazine.On July 1, Chiesi and Fluidda organized an international webinar for pneumologists and other health professionals, discussing the use of Functional Respiratory Imaging during the covid-19 pandemic in three different… View ArticleERS 2020 – Lung Deposition of Two Bronchodilators in Subjects With COPDLung Deposition of Two Bronchodilators in Subjects with COPD When Administered via Standard Jet Nebulizer or HandiHaler® Using FRI. During the ERS Congress 2020, a poster was presented comparing lung deposition of… View ArticleERS 2020 – FRI shows significant regional ventilation defects in COPDFunctional Respiratory Imaging (FRI) shows significant regional ventilation defects in COPD patients as compared to healthy patients Ventilation defects in COPD are associated with reduced exercise tolerance and worse quality… View ArticleERS 2020 – Ventilation-perfusion measures based on FRI correlates with exercise tolerance and PRO’s in COPDVentilation-perfusion measures based on FRI correlates with exercise tolerance in COPD COPD affects the lungs in many ways. A common problem is reduced ventilation-perfusion (V/Q) values caused by airway disease… View ArticleFRI identifies redistribution of pulmonary blood flow in patients with COVID-19Functional respiratory imaging identifies changes in pulmonary blood flow in patients with COVID-19 An common observation is that some patients with COVID-19 have normal lung compliance but significant hypoxaemia different from… View ArticleUse of FRI in deposition of inhaled lip. cyclosporin in BOSUse Of Functional Respiratory Imaging (FRI) To Explore Drug Delivery And Lung Deposition Of Inhaled Liposomal Cyclosporine A (L-CsA-i) In Patients After Lung Transplantation (LTx) FRI-based biomarkers have been investigated as… View ArticleSummer Holiday Card 2020Webcast Mundipharma – July 15th 2020On July 15, from 6 – 7.30 pm GMT, Mundipharma organizes a webinar for pulmonologists and other interested HCP’s on respiratory topics in the focus of interest, such as the… View ArticlePodcast with Dr. Rola on the clinical possibilities of FRIOn July 3rd, Fluidda’s CEO Dr Jan De Backer had a podcast interview with Dr Philippe Rola, president of the critical care unit at the Santa Cabrini Hospital in Montreal,… View ArticleWebinar – Lessons Learned from COVID-19 – Now Available OfflineThis week a very high rated webinar was broadcast where the latest findings on COVID-19 research with FRI-technology was presented by prominent pulmonologists and radiologists from all over the world…. View ArticleWebinar – Lessons learned from the COVID-19 crisisLessons learned from the COVID-19 crisis. This is the title of a webinar Fluidda and Chiesi will broadcast on July 1st at 8 pm CET for interested pulmonologists and other… View ArticleAssessment of small pulmonary blood vessels in COVID-19 patients using HRCTNew publication on FRI: Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT Mounting evidence supports the role of pulmonary hemodynamic alterations in the pathogenesis of COVID-19. Building… View ArticleComparison inhalation with pMDI and pMDI/spacer on drug delivery in the lung using FRI technologyPublished in: Am J Respir Crit Care Med 2020;201:A5689 Authors: J. Suggett1, V. Kushnarev(1) , C. Van Holsbeke (2) , S. Van Steen(2) , B. Mignot(2) 1) Trudell Medical International, London,… View ArticleTheoretical Model of the Pathophysiology of COVID-19 using FRI-data in EMCRIT podcastDuring an EMCRIT podcast last week. Dr. Farid Jalali (Long beach CA) laid out a theoretical framework for the pathophysiology of the lung effects of COVID-19. Take Home Points from this podcast… View ArticleFRI assessment of Glycopyrrolate and FF pMDIs using co-delivery technology in COPDNew published article: FRI assessment of glycopyrrolate and formoterol fumarate pMDI formulations using co-suspension delivery technology in COPD. Understanding lungs and lung diseases has never been more important than in… View ArticleEffectiveness of a new mobile HFCWO device for airway clearance in CF patientsFluidda studied the effectiveness of a new mobile HFCWO device for airway clearance in CF patients. High-frequency chest wall oscillation (HFCWO) is a commonly used airway clearance technique for cystic… View ArticleFull Broadcast – Kathy Ireland InterviewWorldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its viewers with an in-depth opportunity to find solutions to industry problems from some of… View ArticleCOVID-19 – Kathy Ireland InterviewWorldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its viewers with an in-depth opportunity to find solutions to industry problems from some of… View ArticleDiseases and Spirometry – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program: Worldwide Business with Kathy Ireland. (Part three) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleInterview AnnouncementLIVE STREAM ANNOUNCEMENT: Fluidda’s CEO will be interviewed on USA television. Dr. Jan De Backer, Fluidda CEO, was recently interviewed about the company’s work on facilitating diagnosis and treatment of… View ArticleOur consortium on COVID-19LET’S TACKLE COVID-19 IN A CONSORTIUM! In an ongoing effort, Fluidda is collecting several batches of HRCT-scans of COVID19-patients to analyze them with their Functional Respiratory Imaging (FRI) technology in… View ArticleWhat is FRI – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program Worldwide Business with Kathy Ireland. (Part two) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleOur mission and vision – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program Worldwide Business with Kathy Ireland. (Part one) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleAntwerp biotech company improves lung damage predictability using 3D scans.By Pieter Haeck, reporter Belgian newspaper “De Tijd”. April 7, 2020 What is the prognosis for someone infected with the corona virus? Will the patient deteriorate quickly or not? The… View ArticleNew 3D-printed connector for non-invasive ventilation developed by Materialise and Fluidda.Materialise and Fluidda worked together in the development of a 3D-printed Non-Invasive PEEP Mask to Alleviate Ventilator Shortage For several years. Materialise, a Belgian 3D printing company with one of… View ArticleMedtech goes to war with COVID-19 (DeviceTalks Weekly)In the most recent Device Talk podcast, Jan de Backer, CEO of Fluidda, was interviewed about medtech’s essential role in the escalating war against COVID-19. He explains how Fluidda’s proprietary… View ArticleFDA clears Fluidda’s Broncholab platform for use in Clinical PracticeThe US Food and Drug Administration provided market clearance to Fluidda for its Broncholab platform. Broncholab provides a number of Functional Respiratory Imaging (FRI) parameters to physicians via an online… View ArticleAirway volume measurement with FRI identifies IPF progressionIdiopathic pulmonary fibrosis (IPF) is a progressive disease with unclear etiology. IPF patients decline with heterogeneous trajectories. The ability to determine an individual’s disease course is limited to pulmonary function measurement… View ArticleFluidda’s investigational network of FRI sitesFluidda’s investigational FRI sites are located all over the world, enhancing clinical research with FRI locally. Fluidda is the world leader in the field of Functional Respiratory Imaging. This technique combines HRCT scans,… View ArticleFDA – FRI acknowledged important tool for investigating depositionIn a recent article, the Food and Drug Administration (FDA) mentioned Fluidda’s FRI technology as an important tool to investigate regional drug deposition of the extrathoracic region, especially to measure… View ArticleFRI may be able to help in optimizing lung tumor treatmentFunctional Respiratory Imaging (FRI) may be able to help in optimizing lung tumor treatment. It is not enough to only look at nodule size as one parameter to determine treatment… View ArticleBronchial thermoplasty increases airway volumeIn a recent study, 10 patients with unstable, severe asthma were treated with Bronchial Thermoplasty (BT) of the left lung, while the right lung was used as an internal control. Changes in… View ArticleEffectiveness of a mobile HFCWO device for airway clearanceHigh Frequency Chest Wall Oscillation (HFCWO) is a commonly used airway clearance technique for Cystic Fibrosis (CF) patients. At ERS 2019 in Madrid, a poster was presented on this topic…. View ArticleFiGHT Australian wildfiresFluidda helps firefighters! Because of climate change, there is an increasing number of spontaneous wildfires all over the world, as we are now unfortunately experiencing in Australia. Fluidda, the company… View ArticleThe usage of AI in medical imagingAt the ERS 2019 conference in Madrid, our Director of Research and Development of Fluidda, gave his opinion on how Artificial Intelligence can help to improve the prediction of respiratory… View ArticleHappy Holidays 2019 – 2020Fluidda wishes you happy holidays and an inspiring 2020!PhD thesis on using AI in combination with FRIAt the University of Antwerp, Maarten Lanclus, Research & Development director of Fluidda, successfully defended his thesis on the topic of using Artificial Intelligence (A.I.) in combination with FRI to enhance… View ArticleOur corporate responsibility project – ERS 2019At ERS 2019, Cedric van Holsbeke, Chief Technology Officer of Fluidda talks about Fluidda’s corporate responsibility project. Laptops, previously used for patient training purposes and training of clinical sites, have been donated by… View ArticleDDL Conference 11 – 13 December EdinburghThe Drug Delivery to the Lungs (DDL) Conference provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation. Fluidda is actively involved in… View ArticleThe effects of particle size in deposition projects – ERS 2019During the ERS 2019 two posters were presented on the deposition of extrafine vs. non-extrafine formulations of different respiratory drugs in different inhalation devices. Both studies were conducted with Functional… View ArticleHow does FRI compare to spirometry?Functional Respiratory Imaging (FRI) parameters can reduce the number of patients required in clinical trials up to sixteen times compared with spirometry while maintaining adequate power and statistical significance. FRI… View ArticleThe value of Fluidda in respiratory clinical research – ERS 2019Prof. W. De Backer, Chairman of the Board of Fluidda nv, was interviewed at the ERS 2019 conference in Madrid about the insights that lead to the founding of the… View ArticleThe advantages of using FRI in clinical trials – ERS 2019Glenn Leemans, Fluidda’s Chief Operative Officer (COO), was interviewed at the ERS 2019 conference in Madrid. In this interview, Glenn explains why Fluidda’s proprietary functional respiratory imaging (FRI) technique can… View ArticleRSNA 2019 – Annual Congress 1st – 6th December ChicagoFluidda will be present at the annual congress of the Radiological Society of North America (RSNA). This year’s congress will take place during 1-6 December in Chicago, Illinois . The RSNA… View ArticleUsing FRI to detect early wildfire exposure on lung developmentDuring the ERS 2019 conference, Fluidda presented the results of a study which investigated that FRI (Functional Respiratory Imaging) parameters can be a sensitive tool to detect early-life wildfire smoke… View ArticleUnderstanding Mucus in Chronic Obstructive Pulmonary Disease (COPD)Mucus plays a major role in Chronic Obstructive Pulmonary Disease (COPD), especially in the Chronic Bronchitis phenotypes. Mucus increases airway resistance making it harder for the patient to breath. At… View ArticleThe highlights of ERS 2019 by Jan De Backer, CEO of FluiddaAt ERS 2019, Jan de Backer, CEO of Fluidda, explains why during the past years, the treatment of lung diseases is shifting from using more common bronchodilatators to more personalized… View ArticleERS 2019 – We are present with our booth and 7 postersFrom September 28 until October 2, Fluidda will exhibit at the annual conference of the European Respiratory Society (ERS) in Madrid, Spain. During this conference, Fluidda will present 7 posters on… View ArticleFluidda will be present at the Annual Drug Discovery & Development Symposium on Pulmonary Vascular DiseaseThis year’s symposium will take place in Paris on July 1-2. Each year the meeting brings leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial… View ArticleFluidda attends the International Conference of Medical imaging with Deep LearningDuring July 8-10 the International Conference of Medical imaging with Deep Learning takes place in London. The FLUIDDA team, specialised in using advanced A.I. algorithms to extract clinically relevant regional… View ArticleBronchial thermoplasty increases airway volume measured by Functional Respiratory Imaging (FRI)In a recently published study (click here for full article) 10 patients with unstable, severe asthma were treated with bronchial thermoplasty of the left lung, while the right lung was used as an… View Article
